“…Serious adverse events attributed to remifentanil patient-controlled analgesia during labour in The Netherlands. International Journal of obstetric Anesthesia: 2019, 3, p. [22][23][24][25][26][27][28] The Dutch SOP prescribes requirements for the use of remifentanil PCA, such as education for healthcare providers, the procedure to obtain informed consent, maternal monitoring requirements, preparation for the application of the method, treatment for complications and documentation. Since the literature does not provide an operational definition of an SAE related to remifentanil use, we established our two expert teams.…”